Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Ofatumumab for Older Patients and Patients Who Refuse Fludarabine-Based Regimens With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT01113632 is registered in ClinicalTrials.gov with SCRI Development Innovations, LLC as lead sponsor.

NCT NCT01113632
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01113632 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Ofatumumab for Older Patients and Patients Who Refuse Fludarabine-Based Regimens With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Lead sponsor
SCRI Development Innovations, LLC
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2010
Completion date
August 31, 2016
Enrollment
77 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, small lymphocytic lymphoma